NeuCyber Neurotech: China's Bid Against Neuralink

NeuCyber Neurotech, a leading Chinese brain-computer interface startup, admits it's three years behind Elon Musk's Neuralink. Despite this, China has become the first country to approve a BCI medical device for commercial use, and the second to initiate human trials, marking significant progress in the field.

NeuCyber Neurotech, a Chinese state-supported brain-computer interface (BCI) startup, acknowledges its technology lags three years behind Elon Musk's Neuralink. This comes amid an intense race by Beijing to advance BCI technology.

In a significant development, China recently became the first nation to approve a commercially viable invasive BCI medical device. This move signals China's determination to lead in cutting-edge scientific advancements.

The country is also the second, after the United States, to launch human trials for BCI technology, highlighting its commitment to pioneering in this revolutionary sector.